We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

July 21, 2022

Sprint: Virtual Care in Oncology: HCPs and Patient Adoption

Commentary
HealthXL Team & HealthXL Community
&

The HealthXL Sprint 2-part meeting series connects senior leaders across our community to solve the latest health challenges. In our most recent sprint we discussed HCP and patient adoption of virtual care in oncology. In this blog we’ve pulled out the top takeaways from this series. 

5 Key Recommendations: 

#1 Provider motivation for digital health prescriptions: Beyond the potential health benefits to patients, some of the main reasons health care providers (HCPs) prescribe digital health solutions include decreased workload, patient empowerment, ease of data collection, and a fundamental desire to innovate in healthcare delivery. A strong motivator for HCPs is the goal to create improvements to workflow. However, there must be provider trust in a solution in terms of strong evidence and clear data protection. 

#2 Digital tools can help to condense data points rather than create data burden: There’s hesitancy to adopt digital solutions that may affect physician workload or become a burden with excessive data review. Solutions that identify triggers HCPs are already monitoring daily and that can condense data points in an easily understandable way can help reduce physician workload. However, it can be a challenge if a digital solution only covers one aspect of a problem. There’s hesitancy to adopt solutions that aren’t comprehensive enough or that would require more than one solution to meet the patient / physician needs. Physicians are unlikely to use multiple digital solutions to meet a patient’s needs. 

#3 Patients, especially cancer patients, want some element of control over their treatment: However, it can be difficult to get the patient's attention. The key to engagement is demonstrating value to the patient and the care team. Patient’s are engaged through human centered design. Patients need to be invited into the development process in order to introduce digital products that are helpful rather than invasive. Being mindful of how questions are asked and how they may make someone feel are important elements of digital health design, specifically for cancer patients who are undergoing frequent exams and treatments. There needs to be a balance between solutions that help the patient but don’t add a burden to the provider, and solutions that help the provider but are not intrusive and not beneficial to the patient.

#4 Roles and responsibilities of pharma partners: Digital health solutions want to work with pharma partners as they offer access to scale and network. However, there may need to be a shift in the traditional sales team model. Pharma needs to set up dedicated teams that are solution oriented and that can help to convince physicians of their value. There needs to be an alignment of commercial strategies and shared commercial goals between digital solutions and pharma companies. There also needs to be a clarity of the roles and responsibilities of both pharma and the digital health company in order to have aligned expectations. 

#5 Care models in oncology are changing: COVID-19 opened up the at-home model. It can be safer for cancer patients and help health systems have a broader reach. Many treatments are also capable of being delivered at home. There’s value in patients not physically needing space at an institution or having to travel to one. However, digital oncology solutions may need to be drug agnostic in order to add value. Patients may receive frequent changes or adjustments to their treatment which would become a barrier to using solutions that are not drug agnostic. 

Experts Included: Alec Moretti (Director of BD & Commercialization, Twill), Carole Tremonti (VP Clinical Strategy, Project Rōnin), Ivan Jurisic (Business Analyst for Digital Therapeutics, Roche), Jyri Yli-Villamo (Head of Global Strategic Partnerships, Kaiku Health), Karine Soulat (VP marketing Wellthy Therapeutics), Kellee Franklin (Strategy & Innovation, Digital Transformation Leader, HCD Expert, Executive Advisor, Mindful Innovation Labs), Maike Schmitz (Oncology Lead, RoX Health)

*All opinions are the participants’ own and do not necessarily reflect the stance of their respective employers.

Want to join the conversation? Check out our upcoming meetings and events

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: The New Reimbursement Path for Digital Health in Belgium

27th September @ 10AM GMT/5PM AWST

The right commercialization model for a digital health product is a key component of success in this rapidly growing space. Join this masterclass led by Steven Vandeput, PhD, to discuss this topic further.

Featuring
Steven Vandeput, PhD
Steven Vandeput, PhD
Advisor Extramuros & Digital Health, beMedTech
Featuring
Steven Vandeput, PhD
Steven Vandeput, PhD
Advisor Extramuros & Digital Health, beMedTech
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: Translating European Regulatory Guides into Practical Steps for DTx Solutions

27th September @ 10:45AM EDT

Are you trying to commercialize a digital therapeutics (DTx) solution in the European Union (EU)? Would you like to learn practical steps on how to navigate the European regulatory landscape? Keep reading, this masterclass is for you!

Featuring
Stephen Gibney
Stephen Gibney
Quality Director, BlueBridge Technologies
Featuring
Stephen Gibney
Stephen Gibney
Quality Director, BlueBridge Technologies
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Are Pharma Partnerships the Wrong Strategy for DTx Companies?

28th September @ 10AM GMT / 5PM AWST

While the digital therapeutics (DTx) market is increasingly growing, it is still small compared to large players in the healthcare industry such as pharma. Join HealthXL in this peer-to-peer discussion to deep dive into this topic.

Featuring
Eugene Borukhovich
Eugene Borukhovich
COO & Co-Founder of YourCoach.Health
Anna-Maria Heidinger
Anna-Maria Heidinger
Head of Digital Innovation Hub Europe, Daiichi Sankyo Europe GmbH
Featuring
Eugene Borukhovich
Eugene Borukhovich
COO & Co-Founder of YourCoach.Health
Anna-Maria Heidinger
Anna-Maria Heidinger
Head of Digital Innovation Hub Europe, Daiichi Sankyo Europe GmbH
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

What are the Best Business Models for DTx in the US?

4th October @ 10:45AM EDT

What are the best models for DTx in the US in this new reality? How will the business models change in the future? Join us in a peer-to-peer conversation where we will discuss these questions and more!

Featuring
Kal Patel
Kal Patel
CEO & Co-Founder at BrightInsight
Emma Carr, PhD
Emma Carr, PhD
Co-Founder and CSO, Amara Therapeutics
Featuring
Kal Patel
Kal Patel
CEO & Co-Founder at BrightInsight
Emma Carr, PhD
Emma Carr, PhD
Co-Founder and CSO, Amara Therapeutics

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Digital Therapeutics (DTx)
27th September @ 10AM GMT/5PM AWST

Masterclass: The New Reimbursement Path for Digital Health in Belgium

The right commercialization model for a digital health product is a key component of success in this rapidly growing space. Join this masterclass led by Steven Vandeput, PhD, to discuss this topic further.

Steven Vandeput, PhD
Featuring
Steven Vandeput, PhD
Advisor Extramuros & Digital Health, beMedTech
Digital Therapeutics (DTx)
27th September @ 10:45AM EDT

Masterclass: Translating European Regulatory Guides into Practical Steps for DTx Solutions

Are you trying to commercialize a digital therapeutics (DTx) solution in the European Union (EU)? Would you like to learn practical steps on how to navigate the European regulatory landscape? Keep reading, this masterclass is for you!

Stephen Gibney
Featuring
Stephen Gibney
Quality Director, BlueBridge Technologies
Telemedicine & Virtual Care Delivery
28th September @ 10:45AM EDT

What Will the Best Business Models Be for Virtual Care in Diabetes?

Join this meeting to take a deep dive into what the best business models will be in the next few years for virtual care companies in the diabetes space.

Frank Westermann
Featuring
Frank Westermann
Co-Founder & Co-CEO, 9am.health
Digital Therapeutics (DTx)
28th September @ 10AM GMT / 5PM AWST

Are Pharma Partnerships the Wrong Strategy for DTx Companies?

While the digital therapeutics (DTx) market is increasingly growing, it is still small compared to large players in the healthcare industry such as pharma. Join HealthXL in this peer-to-peer discussion to deep dive into this topic.

Eugene Borukhovich
Featuring
Eugene Borukhovich
COO & Co-Founder of YourCoach.Health

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.